Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15764MR)

This product GTTS-WQ15764MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4220MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ7775MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ9646MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ14198MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ13714MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ285MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ15413MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ11794MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW